Neurocrine Biosciences | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
AbbVie USD 9.34B 1.36B 2025-03
Acadia Pharmaceuticals USD 243.83M 19.91M 2025-06
Agios Pharmaceuticals USD 10.75M 3.11M 2025-06
ALKERMES USD 257.77M 462K 2025-06
Alnylam Pharmaceuticals USD 630.74M 107.59M 2025-06
Amgen USD 6.17B 624M 2025-06
Biogen USD 2.04B 238.8M 2025-06
BioMarin Pharmaceutical USD 670.47M 76.89M 2025-06
Cytokinetics 66.77M 165.03M 2025-06
Dynavax Technologies USD 78.57M 24.17M 2025-06
Exelixis USD 548.79M 12.52M 2025-06
Gilead Sciences USD 5.58B 453M 2025-06
Halozyme Therapeutics USD 279.36M 62.9M 2025-06
Incyte USD 1.14B 151.67M 2025-06
Ionis Pharmaceuticals USD 448M 317.85M 2025-06
Neurocrine Biosciences USD 676.2M 112.8M 2025-06
Pfizer USD 10.88B 248M 2025-06
Prothena -59001000 66.45M 2024-09
Regeneron Pharmaceuticals USD 3.15B 581M 2025-06
Repligen USD 91.14M 385K 2025-06
Sarepta Therapeutics USD 457.87M 149.43M 2025-06
Teva Pharmaceutical Industries USD 2.1B 188M 2025-06
Ultragenyx Pharmaceutical USD 143.49M 32.86M 2025-06
Vertex Pharmaceuticals USD 2.56B 150M 2025-06


Neurocrine Biosciences Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Aug 2025.